Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -48.64%. However, over the past six months, we’ve seen a weaker performance of 36.38%. The price of VERV fallen by 24.96% over the last 30 days. And in the last five days, it has surged by 47.63%.
In terms of market performance, Verve Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $19.34 on 02/29/24, and the lowest value was recorded at $4.30 on 08/14/24.
52-week price history of VERV Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Verve Therapeutics Inc’s current trading price is -62.98% away from its 52-week high, while its distance from the 52-week low is 66.32%. The stock’s price range during this period has varied between$4.30 and $19.34. The Verve Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 4.42 million for the day, a figure considerably higher than their average daily volume of 1.36 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Verve Therapeutics Inc (VERV) has experienced a quarterly rise of 17.76% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 588.36M and boasts a workforce of 255 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.67, with a change in price of +0.79. Similarly, Verve Therapeutics Inc recorded 1,406,115 in trading volume during the last 100 days, posting a change of +12.40%.
VERV’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for VERV stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.12.
VERV Stock Stochastic Average
Verve Therapeutics Inc’s raw stochastic average for the past 50 days is presently 95.55%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 95.44%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 67.12% and 57.06%, respectively.
